Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study analyzed FAERS data to explore the risk and onset patterns of autoimmune skin diseases associated with immune checkpoint inhibitors, finding a strong association particularly with bullous pemphigoid and emphasizing the need for vigilant monitoring of these adverse effects.

The laser therapy device effectively increased hair growth in people with androgenetic alopecia.

This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.

This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.

This study found that a supplement containing cystine, B vitamins, and minerals improved hair condition in 34 women with diffuse hair loss over six months, as evidenced by an increased anagen/telogen hair ratio, positive participant feedback, and no serious side effects.

This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.

This study found that oral minoxidil is associated with a higher proportional reporting of several cardiovascular adverse events compared to topical minoxidil in spontaneous FDA reports, but these signals should be interpreted as hypothesis-generating rather than evidence of clinical safety.

This study found that the type of reporter significantly influences the detection of cancer therapy-induced alopecia signals, highlighting differences in signal amplification between patients and healthcare professionals.

This study analyzed data from the FDA Adverse Event Reporting System to evaluate cancer therapy–induced alopecia, finding that reporter type significantly affects signal detection, with docetaxel showing the highest disproportionate association overall, and vismodegib ranking highest among healthcare professional reports.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.

The researchers reported that oral finasteride 1 mg was associated with more frequent reports of sexual adverse events than dutasteride 0.5 mg, particularly after 2012, which may be influenced by the nocebo effect.

This research discussed the historical use of plants as dermatologic remedies and how some botanicals independently gained recognition for their medicinal properties across cultures, contributing to the field of pharmacognosy and modern skincare.

This pilot study found that an 8-week treatment with a hyaluronic acid and hydrogen peroxide gel improved folliculitis symptoms and patient satisfaction, supporting its potential use in dermatologic practice and future trials.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

This study confirmed that methimazole use is associated with agranulocytosis, pyrexia, exposure during pregnancy, and hyperthyroidism, while also identifying new safety signals like premature birth and septic shock that require further investigation.

In this study, the researchers developed a deep learning framework to pre-emptively screen for adverse drug effects, showing strong predictive performance, including for increased bleeding risks with edoxaban compared to other anticoagulants.

This retrospective pharmacovigilance study identified 34 drugs, including finasteride and dutasteride, that may be associated with sexual dysfunction, with a higher risk observed in males aged 31-45.

This study analyzed reports from the FDA Adverse Event Reporting System and observed an upward trend in suicidality-related safety signals among young male finasteride users since 2019, peaking in 2022, highlighting emerging psychiatric safety concerns and the need for vigilant monitoring of this population.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This study utilized the USFDA AERS to identify significant associations between various medications—such as anti-osteoporotic drugs and phenytoin—and gingival disorders, noting emergent signals with finasteride, COVID-19 vaccine, and levothyroxine, suggesting a need for awareness of oral side effects.

In this study, 0.2 mg dutasteride significantly improved hair growth in men with androgenetic alopecia compared to placebo over 24 weeks, showing similar efficacy to the higher 0.5 mg dose with a favorable safety profile.

This case report describes an 18-month-old boy who developed a rare phototoxic skin reaction to terbinafine, likely triggered by sunlight exposure, which resolved after treatment with corticosteroid cream and sun avoidance.

This narrative review reports that well-selected plant extracts and their active compounds may improve hair health by promoting hair growth and preventing hair loss, potentially aiding in developing targeted therapies for alopecia.

In this study, 32 healthy adults with hair fall complaints applied a hair serum daily for 60 days, resulting in statistically significant improvements in hair growth rate, thickness, and density, without any reported adverse events.

This study investigated medications potentially linked to male-factor infertility using the FDA Adverse Event Reporting System and found that finasteride, testosterone, valproate, and other drugs showed significant disproportionate reporting of infertility cases, highlighting a potential under-reporting issue to regulatory bodies.

This study found that a graphene-barium titanate nanosystem can accelerate wound healing by killing bacteria and promoting fibroblast proliferation, demonstrating effectiveness in both Gram-negative and Gram-positive bacteria-infected wounds in mice.

In this study, six types of cold-pressed oils commonly found in the Polish market were analyzed for their health-promoting compounds and antioxidant activity, revealing them as valuable sources of bioactive compounds like polyunsaturated fatty acids, tocopherols, sterols, and polyphenols, without exceeding recommended deterioration parameters.

This study is investigating the efficacy and safety of proxalutamide, an androgen receptor antagonist, in treating severe or critically ill patients with COVID-19, aiming to provide new insights into potential therapeutic options. Results are not reported yet.

This cohort study observed that 42.2% of individuals who tested positive for COVID-19 developed post-COVID syndrome, with higher risks noted in older adults, those with severe initial illness, and unvaccinated individuals in Mukkam Municipality.